BioWorld

Sep. 8, 2004

Deal With Merck Potentially Worth $26M For TransTech

TransTech Pharma Inc. secured another partnership, courtesy of its platform technology, in a collaboration that could be worth at least $26 million to the 5-year-old firm. (BioWorld Today) Read More

MAP Series B Draws $30M For Pediatric Asthma Work

Sunesis, Biogen Idec In Cancer Deal Worth $21 Million Up Front

Vivus Launching Phase III With Female Sex Therapy

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 8, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...